University of British Columbia
Knowledge translation

Rm 291, 2206 East Mall

Vancouver, BC V6T 1Z3

604–822–5550 / 604–806–8712
604–822–4994

Professor

Director, Centre for Health Evaluation and Outcome Sciences

National Director, CIHR Canadian HIV Trials Network

Senior Scientist, Arthritis Research Centre of Canada

PhD, FCAHS

Dr. Anis is a Professor in the School of Population and Public Health (SPPH) at the University of British Columbia (UBC), a respected health economist and sought-after speaker on the topic of economic evaluation and resource allocation for health care interventions. His primary areas of expertise include Canadian competition policy in the pharmaceutical industry and the cost-effectiveness of treatments for HIV/AIDS and rheumatoid arthritis. Dr. Anis is the Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS), one of the largest and most productive multidisciplinary health outcomes research groups in Canada. He is also the National Director of the CIHR Canadian HIV Trials Network (CTN), a Senior Scientist at the Arthritis Research Centre of Canada, and a Fellow of the Canadian Academy of Health Sciences.

Dr. Anis’s research activities have been extensive. His earliest research into the pharmaceutical industry demonstrated that pricing regulations as they were being implemented by provincial drug plans were responsible for higher generic drug prices in Canada. As the founding director of the Pharmacoeconomic Initiative of BC, Dr. Anis developed a framework under which pharmaceutical firms seeking to list drugs on the provincial formulary were required to submit cost-effectiveness data to inform the government’s decision. In the 1990s, Dr. Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of anti-retroviral therapy and his work helped shape economic policies governing access to this critical treatment for persons living with HIV/AIDS. As an expert in cost-effectiveness analysis, Dr. Anis has also made important contributions to arthritis research. In the area of rheumatoid arthritis, Dr. Anis has been involved in several influential studies of biologic therapies, which have informed reimbursement policies surrounding these treatments in Canada and the UK.

Since his recruitment in 1995 to Providence Health Care, home to CHEOS and the CTN, Dr. Anis has fostered a network of world-class scientists in health economics and health services research, driving numerous influential programs to inform health policy. At both CHEOS and the CTN, Dr. Anis leads active research programs in pharmacoeconomics. As the director of CHEOS, Dr. Anis is committed to positive and fruitful working relationships with staff and trainees and their success is a top priority at CHEOS. Dr. Anis values the energy and dedication of his wide network of colleagues and he shares their devotion to health outcomes research benefiting both patients and society.